Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLX030 hemodynamic study in acute heart failure
NL-OMON37099Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Heart Failure (AHF) comparing RLX030 + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Pulmonary capillary wedge pressure, Cardiac index and 4 more. Started Jul 2012; status: active, not recruiting.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NL-OMON37099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37099.